---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-083126"
form_type: "8-K"
ticker: "COLL"
cik: "0001267565"
company_name: "COLLEGIUM PHARMACEUTICAL, INC"
filed_at: "2024-07-29T23:59:59+00:00"
generated_at: "2026-05-31T15:39:16.835234+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Collegium to acquire Ironshore Therapeutics for $525M; Jornay PM ADHD drug; Q2 prelim rev $145M

## Summary
- Acquires Ironshore for $525M cash plus up to $25M milestone if Jornay PM net revenue exceeds defined 2025 threshold.
- Jornay PM (ADHD) expected >$100M net revenue in 2024; H1 2024 prescriptions up 32% YoY.
- Funded by cash on hand and new $646M five-year Pharmakon loan with 300bps rate reduction.
- Preliminary Q2 2024 net product revenue $145M (+7% YoY); reaffirms FY2024 guidance of $580-595M revenue, $380-395M adj EBITDA.
- Director Neil McFarlane resigned immediately due to conflict of interest (CEO of Zevra Therapeutics).

## SEC filing metadata
- accession: 0001104659-24-083126
- form_type: 8-K
- ticker: COLL
- cik: 0001267565
- company_name: COLLEGIUM PHARMACEUTICAL, INC
- filed_at: 2024-07-29T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.02, 2.03, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267565/000110465924083126/0001104659-24-083126-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267565/000110465924083126/tm2420341d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-083126
- JSON: https://secwatch.observer/filing/0001104659-24-083126.json
- Plain text: https://secwatch.observer/filing/0001104659-24-083126.txt

## Key facts
- Executive change
  Neil McFarlane resigned as director at COLLEGIUM PHARMACEUTICAL, INC.
  - Action: resigned
  - Role: director
  source text: On July 28, 2024, Neil McFarlane notified the board of directors of the Company (the “Board”) of his intent to resign from the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267565/000110465924083126/0001104659-24-083126-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.